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Elsevier Taiwan LLC. Open access under CSummary Background: To compare the efficacy of esomeprazole and famotidine against
stress ulcers and the association of these prophylactic agents with ventilator-associated pneu-
monia in patients admitted to neurosurgical intensive care unit (ICU).
Patients and Methods: Sixty patients were randomly allocated into two groups (the esomepra-
zole and famotidine groups; nZ 30 each) to receive prophylaxis medication for 7 days within
24 hours of admission in a neurosurgical ICU. Patients in the esomeprazole group received
esomeprazole (40 mg) dissolved in water once a day through a nasogastric tube, whereas pa-
tients in the famotidine group received an intravenous infusion of famotidine (20 mg) every 12
hours. We then compared the occurrence of overt upper gastrointestinal bleeding and
ventilator-associated pneumonia between these two groups.
Results: One patient in the famotidine group had overt upper gastrointestinal bleeding (3.3%),
whereas the bleeding was not observed in patients in the esomeprazole group. Ventilator-
associated pneumonia occurred in one patient (3.3%) from each group. One patient died within
30 days (3.3%) in the esomeprazole group and three patients (10%) died in the famotidine
group. There was no difference in the occurrence of overt upper gastrointestinal bleeding
(p Z 1.000), ventilator-associated pneumonia (p Z 1.000), and 30-day mortality
(p Z 0.612) between these two groups.
Conclusion: In this small-scale study, the effect of administration of esomeprazole through a
nasogastric tube on stress ulcer was similar to that of intravenous famotidine infusion in neuro-
surgical ICU patients. In addition, the association between prevalence of ventilator-associatedGastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital,
on 2, Banciao, New Taipei 22060, Taiwan.
com.tw (T.-H. Lee).
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Comparison of esomeprazole and famotidine for stress ulcers 51pneumonia and administration of esomeprazole was also similar to that observed with famoti-
dine infusion.
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With improvements in critical care, the occurrence of stress
ulcer bleeding has decreased recently. However, it still oc-
curs and is associatedwithahighmortality rate in critically ill
patients with risk factors, including respiratory failure
requiring mechanical ventilation, sepsis, coagulopathy,
shock, severe burning injury, head injury or intracranial
surgery, and hepatic or renal failure that require major sur-
gery [1,2]. Although treatment with prophylactic agents for
stress ulcer in these patients is still recommended, there is
still no consensus on the choice of drug [3e5].
Stress ulcer is a common complication in neurosurgical
intensive care unit (ICU), often referred as Cushing’s ulcers.
Besides hemodynamic disturbance in critically ill patients,
hypersecretion of gastric acid caused by injury to the
central nervous system plays an important role in the
pathogenesis of Cushing’s ulcers [2,6]. Acid suppression
using histamine-2 receptor antagonists (H2RA) has proven
to be more effective than placebo for stress ulcer and is
most popular in clinical use [3,5,7,8]. Proton pump in-
hibitors (PPIs) are more potent in acid suppression than
H2RA and have been increasingly used for treatment of
stress ulcers recently [9]. A meta-analysis reported by
Pongprasobchai et al [10] demonstrated the superiority of
PPI over H2RA in decreasing clinically important bleeding in
critically ill patients; however, another meta-analysis
revealed a different result [11]. Therefore, this study was
conducted to directly compare the effect of esomeprazole
and famotidine on stress ulcer in neurosurgical ICU.
Patients and methods
From March 2007 to March 2010, we enrolled those patients
who were admitted to the neurosurgical ICU of the Far
Eastern Memorial Hospital, New Taipei, Taiwan for post-
surgical care or management of severe cerebrovascular
accident. Most patients received surgical treatment for
intracranial hemorrhage. After explaining the study pur-
pose and obtaining written consent from their family
members, prophylactic medication was initiated within 24
hours after admission. We excluded those who were aged
less than 18 years, who had history of allergy to either
famotidine or esomeprazole, who could not be fed through
a nasogastric tube, and who already had gastrointestinal
bleeding on admission. This study was approved by the
Research Ethics Review Committee of the Far Eastern Me-
morial Hospital and was monitored during execution.
The patients were randomly allocated to two groups. The
patients in the first group received esomeprazole (40 mg;
Nexium, AstraZeneca, Sodertaije, Sweden) dissolved in
water through a nasogastric tube once per day for 7 days (the
esomeprazole group); the patients in the second group (thefamotidine group) received intravenous famotidine (20 mg;
Gaster, Astellas, Shizuoka, Japan) infusion every 12 hours for
7 days. Most of these patients started their enteral feeding
after admission to the neurosurgical ICU if not contra-
indicated. We recorded the demographic data, operation
time, and baseline data of Glasgow Coma Scale (GCS, last
score prior to the operation or on admission for thosewithout
surgery), Acute Physiology and Chronic Health Evaluation II
Score (AP-II), and intracranial pressure. We counted 1 point
for the patients with endotracheal intubation in the verbal
category of GCS. We recorded vital signs including body
temperature, heart rate, and blood pressure every day for 1
week; patient’s complete blood cell count and chest X-ray
(CXR) were reviewed every other day; and stool occult blood
was tested twice a week for 1 week. Besides, we surveyed
the ICU admission days and 30-day survival rates. We also
monitored and recorded the characteristics of nasogastric
tube drainage, sputum, and stool every day for 1 week. We
focused on the prevention of overt upper gastrointestinal
bleeding in patients receiving stress ulcer prophylactic
agents and defined upper gastrointestinal bleeding as tarry
stool, hematemesis, drainage of more than 60 mL coffee
ground substance from nasogastric tube, or decreased he-
moglobin level more than 2 g/dL with proved lesions by
endoscopic examination. We also defined positive stool
occult blood test as occult bleeding. Guaiac stool occult
blood test was carried out twice a week. If no stool sample
was available on the scheduled day, it would be checked
when the patient passed a stool on the following days during
the study period. We defined ventilator-associated pneu-
monia as pneumonia occurring after 48 hours of ventilator
use that fulfills three or more of the following four criteria:
(1) presence of persistent (>48 hours) or new onset infil-
tration in CXR; (2) positive sputum smear (with <10 epithe-
lial cells per low-power field, 100, and >25 white blood
cells per low-power field or presence of polymorphonuclear
cells with phagocytosis); (3) fever with body temperature
>38.3C; and (4) leukocytosis >12  109/L.
All data were analyzed with the statistical software SPSS
for Windows (SPSS Inc., Chicago, IL, USA). Significant differ-
ence for sexwas comparedwith the Chi-square test, whereas
significant differences for age, operation time, GCS, intra-
cranial pressure, and ICU admission days were comparedwith
the ManneWhitney U test. We used Fisher’s exact tests to
evaluate the differences for apparent upper gastrointestinal
bleeding and microscopic bleeding, ventilator-associated
pneumonia, and 30-daymortality between these two groups.
Results
A total of 60 patients participated in the study, with 30
allocated to the esomeprazole group and 30 to the famo-
tidine group. In the esomeprazole group, 26 patients were
Table 2 Outcome evaluations in the two study groups.
Outcome evaluations Esomeprazole
(n Z 30)
Famotidine
(n Z 30)
p*
Overt UGI bleeding 0 (0) 1 (3.3) >0.99
Occult bleeding 10 (33.3) 10 (33.3) >0.99
Ventilator-associated
pneumonia
1 (3.3) 1 (3.3) >0.99
ICU admission days 23.6  12.40 23.3  12.14 0.842
30-day survival 29 (96.7) 27 (90.0) 0.612
Data are presented as n (%) or mean  SD.
* ICU admission days were compared with ManneWhitney U test
and Fisher’s exact test was used for other variables.
ICU Z intensive care unit; UGI Z upper gastrointestinal.
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rebral infarct, one received transarterial embolization for
intracerebral hemorrhage, and two received intracranial
pressure monitoring for intracranial hemorrhage. In the
famotidine group, 26 patients were operated for intracra-
nial hemorrhage, one for brain tumor, and three received
intracranial pressure monitoring for intracranial hemor-
rhage. Every patient received ventilator support and
nasogastric feeding when admitted to the ICU. In the eso-
meprazole group, there were 20 male and 10 female pa-
tients, with a mean age of 56.2  18.4 years. The average
baseline GCS was 8.0  4.5, AP-II was 16.4  5.6, intra-
cranial pressure was 15.2  13.3 cmH2O. The average
operation time was 235.7  168.1 minutes. In the famoti-
dine group, there were 16 male and 14 female patients,
with a mean age of 59.2  15.0 years. The baseline GCS was
7.3  4.1, AP-II was 17.7  6.2, intracranial pressure was
12.4  9.4 cmH2O. The average operation time was
293.0  246.8 minutes. There was no significant difference
for sex (pZ 0.292), age (pZ 0.473), GCS (pZ 0.599), AP-II
(p Z 0.370), intracranial pressure (p Z 0.667), and oper-
ation time (pZ 0.232) between these two groups (Table 1).
In the esomeprazole group, none of the patients had
overt upper gastrointestinal bleeding, 10 (33%) had occult
bleeding, and one (3.3%) had ventilator-associated pneu-
monia. By contrast, in the famotidine group, one patient
(3.3%) had overt upper gastrointestinal bleeding, 10 (33%)
had occult bleeding, and one (3.3%) had ventilator-
associated pneumonia. The patient with overt upper
gastrointestinal bleeding did not undergo endoscopic ex-
amination due to concern of significant risk during the im-
mediate postoperative period. There was no difference for
overt upper gastrointestinal bleeding (p Z 1.000), occult
bleeding (pZ 1.000), and ventilator-associated pneumonia
(p Z 1.000) between these two groups. The ICU admission
days were 23.6  12.40 days in the esomeprazole group and
23.3  12.14 days in the famotidine group and no statistical
difference was noted (p Z 0.842). One patient died (3.3%)
within 30 days in the esomeprazole group, whereas three
patients (10%) died in the famotidine group. The 30-day
survival rate showed no statistical difference (p Z 0.612;
Table 2).Table 1 Distributions of baseline characteristics in the
two study groups.
Baseline
characteristics
Esomeprazole
(n Z 30)
Famotidine
(n Z 30)
p*
Male 20 (66.7) 16 (53.3) 0.292
Age (y) 56.2  18.4 59.2  15.0 0.473
GCS 8.0  4.5 7.3  4.1 0.599
AP-II 16.4  5.6 17.7  6.2 0.370
ICP (cmH2O) 15.2  13.3 12.4  9.4 0.607
OP time (min) 235.7  168.1 293.0  246.8 0.232
Data are presented as n (%) or mean  SD.
* Comparisons between two groups: Chi-square test was used to
examine the difference in sex and ManneWhitney U test was
used for other variables.
AP-IIZ Acute Physiology and Chronic Health Evaluation II Score;
GCS Z Glasgow Coma Scale; ICP Z intracranial pressure;
OP Z operation.Discussion
In our small study group, none of the patients in the eso-
meprazole group had overt upper gastrointestinal bleeding;
by contrast, one patient (3.3%) in the famotidine group had
overt upper gastrointestinal bleeding, but no significant
difference was found between the two groups. The inci-
dence rate was similar to that of previous studies (between
3% and 6% for clinically important bleeding) that used
prophylactic agents for treating stress ulcer [12,13]. There
was also no difference in the occurrence of ventilator-
associated pneumonia between the esomeprazole and
famotidine groups (3.3% in both groups). Although occult
bleeding does not predict the development of clinically
significant bleeding [14], it was also evaluated in this study.
A significant proportion of patients (33%) in neurosurgical
ICU developed occult bleeding in both the esomeprazole
and famotidine groups; however, no difference was found
between the two groups.
At present, proton pumper inhibitors are the most
potent acid inhibitors available. They have gained more
popularity as stress ulcer prophylactic agents recently
despite the absence of strong evidence supporting their
use. Conrad et al [15] demonstrated that omeprazole oral
suspension provided better acid control than intravenous
cimetidine in critically ill patients. A previous small pilot
study revealed a better efficacy of omeprazole over ranit-
idine for treating stress ulcers [16]. A meta-analysis re-
ported by Pongprasobchai et al [10] also showed the
superiority of PPI over H2RA in decreasing clinically
important bleeding in critically ill patients. However,
another meta-analysis by Lin et al [11] revealed a different
result. A randomized controlled study performed by Kant-
orova et al [17] demonstrated that omeprazole, famotidine,
and sucralfate prophylaxis could not affect the already very
low incidence of clinically important stress-related
bleeding in surgical ICU when compared with the placebo.
Early enteral nutrition has been promoted in critically ill
patients in recent years, with probable benefits for treating
stress ulcer [18,19]. This strategy was adapted in our
neurosurgical ICU and might have contributed to the low
incidence of apparent upper gastrointestinal bleeding in
our patients. Marik et al [20] concluded in their meta-
analysis that treating stress ulcer with H2RA may not be
needed in those patients receiving enteral feeding, and
such therapy may actually increase the risk of pneumonia
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and thus definite recommendations regarding the role of
enteral feeding in treating stress ulcer are not possible
[18,19]. Therefore, the use of enteral feeding as the only
therapeutic approach for stress ulcer prophylaxis should
not be encouraged until definite data are available [19].
Stress ulcer prophylaxis has become a standard of care
for critical patients for more than two decades. However,
there were some reports concerning its overuse in critical
settings [21] and even in general medical patients [22,23].
The issues of overutilization of PPIs for gastroesophageal
reflux disease and stress ulcer prophylactic agents were
also proposed [9]. Considering its cost effectiveness and
potential risk, judicious use of stress ulcer prophylactic
agents in high-risk patients is important for critical care.
From the literature review to-date, no significant differ-
ence in efficacy and risk of nosocomial pneumonia was
demonstrated when comparing different drugs for stress
ulcer [24,25]. Our study had a similar result and provided a
cheaper regimen of an oral form of esomeprazole given
through a nasogastric tube in suitable patients.
There are several limitations in our study. The case
number is relatively small to draw a strong conclusion. It
was carried out in only one hospital and the studied results
cannot be generalized for practice. We did not collect all
the relevant clinical data for analysis, such as history of
ulcer or bleeding, use of nonsteroid anti-inflammatory
drugs, aspirin, and steroids. Besides, we only provided
prophylactic agents to those patients for the initial 7 days
after admission, and the following days were not consid-
ered in the analysis.
In conclusion, our small-scale study demonstrated that
esomeprazole given through a nasogastric tube could pro-
vide a simple, effective approach for the treatment of a
stress ulcer without an increased risk of ventilator-
associated pneumonia in patients admitted to neurosur-
gical ICU.Conflicts of interest
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